Radiopharmaceutical Validation for Clinical Use

Radiopharmaceuticals are reemerging as attractive anticancer agents, but there are no universally adopted guidelines or standardized procedures for evaluating agent validity before early-phase trial implementation. To validate a radiopharmaceutical, it is desirous for the radiopharmaceutical to be s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunos, Charles A., Howells, Rodney, Chauhan, Aman, Myint, Zin W., Bernard, Mark E., El Khouli, Riham, Capala, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966985/
https://www.ncbi.nlm.nih.gov/pubmed/33747951
http://dx.doi.org/10.3389/fonc.2021.630827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966985/
https://www.ncbi.nlm.nih.gov/pubmed/33747951
http://dx.doi.org/10.3389/fonc.2021.630827

Ejemplares similares